129 related articles for article (PubMed ID: 2383162)
1. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial.
Caperton EM; Heim-Duthoy KL; Matzke GR; Peterson PK; Johnson RC
Arch Intern Med; 1990 Aug; 150(8):1677-82. PubMed ID: 2383162
[TBL] [Abstract][Full Text] [Related]
2. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.
Klempner MS; Hu LT; Evans J; Schmid CH; Johnson GM; Trevino RP; Norton D; Levy L; Wall D; McCall J; Kosinski M; Weinstein A
N Engl J Med; 2001 Jul; 345(2):85-92. PubMed ID: 11450676
[TBL] [Abstract][Full Text] [Related]
3. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy.
Bentas W; Karch H; Huppertz HI
J Rheumatol; 2000 Aug; 27(8):2025-30. PubMed ID: 10955347
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses to Borrelia burgdorferi in patients with antibiotic-refractory, antibiotic-responsive, or non-antibiotic-treated Lyme arthritis.
Kannian P; McHugh G; Johnson BJ; Bacon RM; Glickstein LJ; Steere AC
Arthritis Rheum; 2007 Dec; 56(12):4216-25. PubMed ID: 18050219
[TBL] [Abstract][Full Text] [Related]
5. [The recurrence of Lyme arthritis].
Łapiński TW; Grzeszczuk A; Prokopowicz D
Pol Merkur Lekarski; 2003 Mar; 14(81):236-8. PubMed ID: 12914103
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and treatment of Lyme arthritis].
Przytuła L; Gińdzieńska-Sieśkiewicz E; Sierakowski S
Przegl Epidemiol; 2006; 60 Suppl 1():125-30. PubMed ID: 16909789
[TBL] [Abstract][Full Text] [Related]
8. Chronic neurologic manifestations of Lyme disease.
Logigian EL; Kaplan RF; Steere AC
N Engl J Med; 1990 Nov; 323(21):1438-44. PubMed ID: 2172819
[TBL] [Abstract][Full Text] [Related]
9. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
11. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Wells WG; Woods GL; Jiang Q; Gesser RM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis subsequent to Borrelia burgdorferi infection in two dogs.
Roush JK; Manley PA; Dueland RT
J Am Vet Med Assoc; 1989 Oct; 195(7):951-3. PubMed ID: 2793577
[TBL] [Abstract][Full Text] [Related]
13. Temporomandibular joint involvement caused by Borrelia Burgdorferi.
Lesnicar G; Zerdoner D
J Craniomaxillofac Surg; 2007 Dec; 35(8):397-400. PubMed ID: 17942315
[TBL] [Abstract][Full Text] [Related]
14. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis.
Gross DM; Steere AC; Huber BT
J Immunol; 1998 Jan; 160(2):1022-8. PubMed ID: 9551943
[TBL] [Abstract][Full Text] [Related]
15. Seronegative Lyme arthritis caused by Borrelia garinii.
Dejmková H; Hulínska D; Tegzová D; Pavelka K; Gatterová J; Vavrík P
Clin Rheumatol; 2002 Aug; 21(4):330-4. PubMed ID: 12189466
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients.
Glatz M; Golestani M; Kerl H; Müllegger RR
Arch Dermatol; 2006 Jul; 142(7):862-8. PubMed ID: 16847202
[TBL] [Abstract][Full Text] [Related]
18. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.
Orozco H; Arch J; Medina-Franco H; Pantoja JP; González QH; Vilatoba M; Hinojosa C; Vargas-Vorackova F; Sifuentes-Osornio J
Arch Surg; 2006 Feb; 141(2):150-3; discussion 154. PubMed ID: 16490891
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
20. [AV-block II and arthritis as manifestations of Lyme borreliosis].
Aringer M; Pirich C; Wenger S; Kiener HP; Machold K; Stanek G; Graninger WB
Wien Med Wochenschr; 1995; 145(7-8):195-6. PubMed ID: 7610673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
